|
- We make healthy possible - Amneal Pharmaceuticals
Amneal Receives U S FDA Approval for Brekiya® (dihydroergotamine mesylate) autoinjector for the Acute Treatment of Migraine and Cluster Headache Episodes See Warning Do not take Brekiya autoinjector with strong CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics
- Our Story - Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceuticals company We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 generic and specialty pharmaceuticals, primarily within the United States
- Our Milestones - Amneal Pharmaceuticals
Amneal acquires a liquid Rx manufacturing R D plant in Branchburg, New Jersey, along with multiple ANDAs and product development IP from KVD That same year, the company acquires all assets related to five generic drugs divested by Merck KGaA and launches the Amneal label, going directly to market via its acquisition of Akyma
- Generic Products - Amneal Pharmaceuticals
We distribute our products through deeply-held relationships with customers, who for 20+ years have associated the Amneal name with an unwavering commitment to quality, service and value You can find our products at pharmacies and healthcare institutions throughout the U S and Puerto Rico and in select international markets
- Our Portfolio - Amneal Pharmaceuticals
We are also excited about our work to bring patients more affordable biologic therapy options through our Biosciences, which includes a broad portfolio of institutional injectables as well as Amneal’s growing biosimilars portfolio And we’re expanding our business across select international markets Learn more about our product portfolios:
- Amneal Pharmaceuticals, Inc. - News - Press Releases
Amneal at-a-glance; Our Founders; Our Milestones; Our Purpose Commitments; Our Culture Rise, Lead, Succeed; Our Leadership Executive Leadership; Board of Directors; Our Locations; Responsibility The Amneal Patient Assistance Programs; Product Donations; National Local Philanthropy; Compliance and Ethics; Patient Community Connections
- Amneal Pharmaceuticals, Inc. - Investor Relations
Amneal is a global, diversified biopharmaceutical company that provides access to high-quality, affordable, and essential medicines Press Releases Stock Information 7 94 AMRX (NASDAQ) + 0 04 + 0 51% Volume: 2,147,500 Pricing delayed 20 minutes 6 18 2025 04:00 PM In This Section
- Amneal at-a-glance - Amneal Pharmaceuticals
Amneal at-a-glance Our company vitals are strong OUR PORTFOLIO FOCUS Complex Generics Specialty Products Oncology Biosimilars Institutional Injectables COMPANY FOUNDING 2002 TOTAL EMPLOYEES 8,000+ TOTAL PRODUCTS 280+ SPECIALTY PRODUCTS ~10 GENERICS PIPELINE 93% non-oral solids BIOSIMILARS 3
|
|
|